Therapeutic Effects of Adalimumab Biosimilars on Rheumatoid Arthritis

Abstract

Rheumatoid arthritis (RA) is a chronic and autoimmune disease. Adalimumab and its generic drugs exerted an effective therapeutic effect on RA. Adalimumab is a monoclonal antibody against CD20. Adalimumab can specifically bind to tumor necrosis factor TNF-α, prevent TNF-α from binding to TNF-α receptors p75 and p55 on the cell surface, and inhibit the biological activity of TNF-α. This article summarizes several generic drugs, including ABP 501, BI 695501, PF-06410293, SB5, FKB327, LBAL, MSB11022, GP2017, etc. The limitation of the study is that it did not evaluate the quality of the research methods as a criterion for inclusion or exclusion in evaluating generic drugs. This article mainly focuses on the generic drugs of Adalimumab, reflecting the differences and similarities between the Adalimumab group and the generic drug group. In addition, the pharmacokinetics, safety, and efficacy of Adalimumab generic drugs were evaluated in several clinical trials. Future research may focus on generating drugs with higher safety, lower costs, and higher efficacy.